Baseline characteristics of the study population (n = 100)
| Characteristics . | . |
|---|---|
| Male | 62% |
| Age, y, median (IQR) | 62 (39–70) |
| Initial therapy: RVD alone/RVD + ASCT | 50%/50% |
| Time from diagnosis to PCD treatment, y, median (IQR) | 3.6 (3.1-4.2) |
| Time from stopping lenalidomide maintenance to PCD treatment, mo, median (IQR) | 22.6 (16.7-29.5) |
| World Health Organization performance status (0 or 1) | 97% |
| Type of myeloma | |
| Immunoglobulin G | 73% |
| Immunoglobulin A | 15% |
| Light chain | 10% |
| Other | 2% |
| International Staging System | |
| I | 67% |
| II | 12% |
| III | 6% |
| Unknown | 15% |
| Serum lactate dehydrogenase | |
| Normal | 77% |
| Elevated | 21% |
| Unknown | 2% |
| Cytogenetic abnormalities | |
| Standard risk | 69% |
| High risk: del 17p or t(14;16) or t(14;16) | 12% |
| Unknown | 19% |
| Plasmacytoma | 5% |
| Characteristics . | . |
|---|---|
| Male | 62% |
| Age, y, median (IQR) | 62 (39–70) |
| Initial therapy: RVD alone/RVD + ASCT | 50%/50% |
| Time from diagnosis to PCD treatment, y, median (IQR) | 3.6 (3.1-4.2) |
| Time from stopping lenalidomide maintenance to PCD treatment, mo, median (IQR) | 22.6 (16.7-29.5) |
| World Health Organization performance status (0 or 1) | 97% |
| Type of myeloma | |
| Immunoglobulin G | 73% |
| Immunoglobulin A | 15% |
| Light chain | 10% |
| Other | 2% |
| International Staging System | |
| I | 67% |
| II | 12% |
| III | 6% |
| Unknown | 15% |
| Serum lactate dehydrogenase | |
| Normal | 77% |
| Elevated | 21% |
| Unknown | 2% |
| Cytogenetic abnormalities | |
| Standard risk | 69% |
| High risk: del 17p or t(14;16) or t(14;16) | 12% |
| Unknown | 19% |
| Plasmacytoma | 5% |